HK1217100A1 - 檢測和治療阿爾茨海默病和相關疾病的化合物和組合物 - Google Patents

檢測和治療阿爾茨海默病和相關疾病的化合物和組合物

Info

Publication number
HK1217100A1
HK1217100A1 HK16104068.1A HK16104068A HK1217100A1 HK 1217100 A1 HK1217100 A1 HK 1217100A1 HK 16104068 A HK16104068 A HK 16104068A HK 1217100 A1 HK1217100 A1 HK 1217100A1
Authority
HK
Hong Kong
Prior art keywords
compositions
compounds
detection
treatment
related disorders
Prior art date
Application number
HK16104068.1A
Other languages
English (en)
Inventor
David R Elmaleh
Timothy Shoup
Hongning Fu
Original Assignee
Massachusetts Gen Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Gen Hospital filed Critical Massachusetts Gen Hospital
Publication of HK1217100A1 publication Critical patent/HK1217100A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/18—Ethers having an ether-oxygen atom bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C43/196—Ethers having an ether-oxygen atom bound to a carbon atom of a ring other than a six-membered aromatic ring containing hydroxy or O-metal groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/18—Ethers having an ether-oxygen atom bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C43/192—Ethers having an ether-oxygen atom bound to a carbon atom of a ring other than a six-membered aromatic ring containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/235—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring and to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C43/253—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring and to a carbon atom of a ring other than a six-membered aromatic ring containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/12—Acetic acid esters
    • C07C69/21—Acetic acid esters of hydroxy compounds with more than three hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/62—Halogen-containing esters
    • C07C69/63—Halogen-containing esters of saturated acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/10—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals directly attached to heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HK16104068.1A 2008-03-21 2016-04-11 檢測和治療阿爾茨海默病和相關疾病的化合物和組合物 HK1217100A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3857108P 2008-03-21 2008-03-21

Publications (1)

Publication Number Publication Date
HK1217100A1 true HK1217100A1 (zh) 2016-12-23

Family

ID=41091569

Family Applications (2)

Application Number Title Priority Date Filing Date
HK11111431.1A HK1157323A1 (zh) 2008-03-21 2011-10-24 檢測和治療阿爾茨海默病和相關疾病的化合物和組合物
HK16104068.1A HK1217100A1 (zh) 2008-03-21 2016-04-11 檢測和治療阿爾茨海默病和相關疾病的化合物和組合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK11111431.1A HK1157323A1 (zh) 2008-03-21 2011-10-24 檢測和治療阿爾茨海默病和相關疾病的化合物和組合物

Country Status (9)

Country Link
US (5) US8450466B2 (zh)
EP (2) EP3231804B1 (zh)
JP (3) JP5501339B2 (zh)
CN (2) CN104974024B (zh)
AU (1) AU2009225407B2 (zh)
CA (2) CA2718035C (zh)
HK (2) HK1157323A1 (zh)
MX (1) MX2010010314A (zh)
WO (1) WO2009117728A2 (zh)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9017724B2 (en) 2004-02-24 2015-04-28 The General Hospital Corporation Catalytic radiofluorination
US8257680B1 (en) 2004-02-24 2012-09-04 The General Hospital Corporation Catalytic radiofluorination
CN104974024B (zh) * 2008-03-21 2017-11-14 综合医院公司 检测和治疗阿尔茨海默病和相关疾病的化合物和组合物
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
NZ607257A (en) * 2010-08-16 2015-02-27 Cognoptix Inc System and method for detecting amyloid proteins
CA2824858A1 (en) 2011-01-18 2012-07-26 General Atomics Hydrolase enzyme substrates and uses thereof
EP3563849A3 (en) 2012-10-25 2020-02-12 The General Hospital Corporation Combination therapies for the treatment of alzheimer's disease and related disorders
US10058530B2 (en) 2012-10-25 2018-08-28 The General Hospital Corporation Combination therapies for the treatment of Alzheimer's disease and related disorders
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
CA2928028A1 (en) 2013-10-22 2015-04-30 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
CA2942975C (en) * 2014-03-19 2023-08-29 Amydis Diagnostics, Inc. Substituted acrylamide and substituted ethenesulfonamide derivatives and pharmaceutical compositions thereof useful as amyloid targeting agents
CN116889562A (zh) 2016-08-31 2023-10-17 通用医疗公司 与神经退行性疾病相关的神经炎症中的巨噬细胞/小胶质细胞
WO2018062588A1 (ko) 2016-09-29 2018-04-05 한국원자력연구원 커큐민 유도체, 이의 제조방법 및 이를 포함하는 베타-아밀로이드 플라크 검출용 광음향 영상화제
AU2017423862A1 (en) 2017-07-20 2020-02-06 Aztherapies, Inc. Powdered formulations of cromolyn sodium and ibuprofen
AU2019299347A1 (en) 2018-07-02 2021-01-21 Aztherapies, Inc. Powdered formulations of cromolyn sodium and alpha-lactose
MX2021002002A (es) 2018-08-23 2021-05-31 Seagen Inc Anticuerpos anti inmunorreceptor de celulas t con dominios ig y motivo inhibidor inmunorreceptor basado en tirosina (tigit).
WO2023150739A2 (en) * 2022-02-07 2023-08-10 Moskovitz Martin J Cryo-surgical device and materials and method of use thereof

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1009897A (en) 1911-03-27 1911-11-28 Us Electrographic Company Projection apparatus.
CH375356A (de) 1959-03-25 1964-02-29 Sandoz Ag Verfahren zur Herstellung von neuen substituierten Succinimiden
CH449628A (de) 1962-04-16 1968-01-15 Sandoz Ag Verfahren zur Herstellung substituierter Succinimide
US3207780A (en) * 1962-11-15 1965-09-21 Upjohn Co 1-deoxy-1-guanidino-3-o-carbamoyl-scyllo-inositol and acylates thereof
US4069262A (en) 1977-03-07 1978-01-17 E. I. Du Pont De Nemours And Company Preparation of 2-fluoronitrobenzene
FR2498594A1 (fr) 1981-01-23 1982-07-30 Rhone Poulenc Ind Procede de preparation de monoesters d'acides carboxyliques b,g-insatures
US4446123A (en) 1982-10-13 1984-05-01 Hahnemann University Process of radioimaging the myocardium of mammals utilizing radiolabeled lipophilic cations
NL8401907A (nl) 1983-06-27 1985-01-16 Sandoz Ag Spirosuccinimiden en werkwijzen voor het bereiden en toepassen van deze spirosuccinimiden.
BE900003A (fr) * 1983-06-27 1984-12-27 Sandoz Sa Derives du spirosuccinimide utilisables comme medicaments.
US4606908A (en) 1983-10-04 1986-08-19 Washington Research Foundation Methods and compositions for plasma and organ imaging
EP0273659A1 (en) * 1986-12-27 1988-07-06 Takeda Chemical Industries, Ltd. Azaspiro compounds, their production and use
US4847082A (en) * 1987-01-21 1989-07-11 Robert Sabin Method of treatment of Alzheimer's disease using phytic acid
US5852029A (en) * 1990-04-10 1998-12-22 Israel Institute For Biological Research Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity
SE465348B (sv) 1990-06-14 1991-08-26 Nils Elander Mikrovaagsanordning foer behandling av precessvaetskor
US5139034A (en) * 1990-11-15 1992-08-18 Philip Morris Incorporated Smoking compositions containing a menthol-release additive
IT1244546B (it) * 1991-02-01 1994-07-15 Mediolanum Farmaceutici Spa Analoghi del fosfatidilinositolo inibitori della fosfolipasi c fosfatidilinositolo-specifica
US5315043A (en) 1992-02-05 1994-05-24 E. I. Du Pont De Nemours And Company Aromatic nucleophilic fluorination
US5264570A (en) * 1992-08-05 1993-11-23 General Electric Company Method for making 2-[18 F]fluoro-2-deoxy-D-glucose
US5493026A (en) 1993-10-25 1996-02-20 Organix, Inc. Substituted 2-carboxyalkyl-3-(fluorophenyl)-8-(3-halopropen-2-yl) nortropanes and their use as imaging for agents for neurodegenerative disorders
US6168776B1 (en) 1994-07-19 2001-01-02 University Of Pittsburgh Alkyl, alkenyl and alkynyl Chrysamine G derivatives for the antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
WO1997026919A2 (en) 1996-01-24 1997-07-31 Warner-Lambert Company Method of imaging amyloid deposits
JP3816570B2 (ja) * 1996-02-16 2006-08-30 塩水港精糖株式会社 アシル化剤
TW593290B (en) 1996-05-10 2004-06-21 Janssen Pharmaceutica Nv Alkylaminobenzothiazole and -benzoxazole derivatives
DE19624705A1 (de) * 1996-06-20 1998-01-08 Deutsches Krebsforsch Dendrimere auf Saccharid-Basis
US5817877A (en) 1996-09-23 1998-10-06 Yale University Metal-catalyzed amination of organic sulfonates to organic amines
US6187286B1 (en) 1996-12-27 2001-02-13 The General Hospital Corporation Tumor imaging agents, methods and kits
WO1998055153A1 (en) 1997-06-04 1998-12-10 The University Of Tennessee Research Corporation Non-steroidal radiolabeled agonist/antagonist compounds and their use in prostate cancer imaging
EP1011738A1 (en) 1997-09-08 2000-06-28 The General Hospital Corporation Imaging agents for early detection of cardiovascular plaque
JP4177472B2 (ja) * 1997-10-02 2008-11-05 株式会社横浜国際バイオ研究所 窒素官能基を含有するアシル化剤及びその製造法
US6660832B1 (en) 1999-08-20 2003-12-09 Isis Pharmaceuticals, Inc. Macrocyclic compounds and preparation methods thereof
EP1218351B1 (en) 1999-09-13 2005-04-20 Pola Chemical Industries, Inc. Nitroimidazole derivative and diagnostic imaging agent containing the same
ATE265994T1 (de) 2000-06-12 2004-05-15 Univ Florida Verfahren zur herstellung von fluorierten benzolen
UY27003A1 (es) 2000-11-06 2002-07-31 Schering Ag Productos radiofarmacéuticos para el diagnóstico de la enfermedad de alzheimer
CN100422180C (zh) 2001-04-23 2008-10-01 宾夕法尼亚州大学理事会 淀粉样斑块聚集抑制剂和诊断成像剂
CA2474142C (en) 2002-02-06 2013-02-05 The Johns Hopkins University Non-invasive diagnostic imaging technology for mitochondria dysfunction using radiolabeled lipophilic salts
DE10210195B4 (de) * 2002-03-07 2005-12-15 Schwarz Pharma Ag Verwendung von 1,3-Diazaspiro-[4,5]decan-2,4-dithion zur Behandlung von Schmerz
US20080063599A1 (en) 2002-11-18 2008-03-13 Jorge Setoain Quinquer Compounds Which Can Be Used To Diagnose And Monitor Diseases Associated With The Formation Of Amyloid Protein Fibrils
CN101385722A (zh) * 2003-02-27 2009-03-18 乔安妮·麦克劳林 预防、治疗和诊断蛋白聚集疾病的方法
US7521481B2 (en) * 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
GB0304640D0 (en) 2003-02-28 2003-04-02 Novartis Ag Organic compounds
US7295831B2 (en) 2003-08-12 2007-11-13 3E Technologies International, Inc. Method and system for wireless intrusion detection prevention and security management
AU2003304416A1 (en) 2003-08-13 2005-03-07 Bf Research Institute, Inc. Probe for disease with amyloid deposit, amyloid-staining agent, remedy and preventive for disease with amyloid deposit and diagnostic probe and staining agent for neurofibril change
US9017724B2 (en) 2004-02-24 2015-04-28 The General Hospital Corporation Catalytic radiofluorination
US8257680B1 (en) 2004-02-24 2012-09-04 The General Hospital Corporation Catalytic radiofluorination
AU2005216949B2 (en) 2004-02-24 2011-09-22 The General Hospital Corporation Catalytic radiofluorination
KR100578732B1 (ko) * 2004-03-05 2006-05-12 학교법인 포항공과대학교 분자 수송체로서의 이노시톨 유도체 및 이의 제조방법
AU2005304931A1 (en) * 2004-11-05 2006-05-18 Wyeth Pet and magnetic resonance for screening Alzheimer's disease therapeutics
JP2008520589A (ja) 2004-11-17 2008-06-19 ジョアン マクローリン， シロイノシトール誘導体を含む組成物およびタンパク質凝集障害を治療するための方法
US7138540B1 (en) 2005-09-06 2006-11-21 Institute Of Nuclear Energy Research Convenient method for the preparation of new precursor of no-carrier-added O-(2-[18F]fluoroethyl)-L-Tyrosine)
JP2009511568A (ja) 2005-10-13 2009-03-19 ワラタ ファーマシューティカルズ， インコーポレイテッド イノシトール誘導体、ならびに異常なタンパク質の折りたたみまたは凝集、あるいはアミロイドの形成、沈着、蓄積または残存を特徴とする疾患の処置におけるその使用
JP2007194369A (ja) * 2006-01-18 2007-08-02 Toei Kogyo Kk 高出力Ｅｒ：ＹＡＧレーザ装置
NO325976B1 (no) * 2006-01-26 2008-08-25 Gba Marine As Anordning for absorpsjon av gass eller damp i vaeske og fremgangsmate ved reintrodusering av damp eller gass i vaeske som gassen eller dampen stammer fra
US20070197452A1 (en) * 2006-02-17 2007-08-23 Mclaurin Joanne Treatment of amyloid-related diseases
AU2007348145A1 (en) 2007-03-01 2008-09-04 Bayer Schering Pharma Aktiengesellschaft 18F fluoro-benzoyl labelled biological active coumpounds as diagnositic imaging agents as well as benzotriazol-1-yloxy-benzoyl, 2,5-dioxo-pyrrolidin-1-yloxy) benzoyl and trimethylammonio-benzoyl precursers
WO2009014203A1 (ja) * 2007-07-26 2009-01-29 Hokko Chemical Industry Co., Ltd. （１，３，５／２，４，６）－１－フルオロ－２，３，４，５，６－シクロヘキサンペントールの製造方法
CN104974024B (zh) 2008-03-21 2017-11-14 综合医院公司 检测和治疗阿尔茨海默病和相关疾病的化合物和组合物
CN102292461A (zh) 2008-12-22 2011-12-21 拜耳先灵医药股份有限公司 使用交换树脂合成放射性核素标记的化合物的方法
GB201216017D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
WO2014052454A1 (en) 2012-09-25 2014-04-03 The Regents Of The University Of Michigan Imaging agents
WO2016070074A1 (en) 2014-10-31 2016-05-06 The General Hospital Corporation F-18 labeled tracer and methods of manufacture

Also Published As

Publication number Publication date
EP2268647A4 (en) 2011-05-18
CN102046638A (zh) 2011-05-04
AU2009225407A1 (en) 2009-09-24
EP3231804B1 (en) 2021-03-03
US9005578B2 (en) 2015-04-14
CN104974024B (zh) 2017-11-14
JP2014177457A (ja) 2014-09-25
CA2718035C (en) 2017-10-24
US20190381199A1 (en) 2019-12-19
HK1157323A1 (zh) 2012-06-29
US20210338849A1 (en) 2021-11-04
JP2017075173A (ja) 2017-04-20
JP5501339B2 (ja) 2014-05-21
JP6140090B2 (ja) 2017-05-31
EP2268647A2 (en) 2011-01-05
EP3231804A1 (en) 2017-10-18
US20110060138A1 (en) 2011-03-10
US10857247B2 (en) 2020-12-08
CN102046638B (zh) 2015-06-03
JP6370361B2 (ja) 2018-08-08
CA2718035A1 (en) 2009-09-24
CA2978149C (en) 2019-02-12
WO2009117728A3 (en) 2010-02-18
EP2268647B1 (en) 2017-01-25
AU2009225407B2 (en) 2013-09-05
WO2009117728A2 (en) 2009-09-24
US20130315827A1 (en) 2013-11-28
US8450466B2 (en) 2013-05-28
CA2978149A1 (en) 2009-09-24
CN104974024A (zh) 2015-10-14
JP2011515417A (ja) 2011-05-19
US20150098903A1 (en) 2015-04-09
MX2010010314A (es) 2011-04-12

Similar Documents

Publication Publication Date Title
HK1217100A1 (zh) 檢測和治療阿爾茨海默病和相關疾病的化合物和組合物
EP2007385A4 (en) CARDIOVASCULAR COMPOSITION AND ITS USE FOR THE TREATMENT OF MORBUS ALZHEIMER
HRP20130357T1 (en) Novel compounds useful for the treatment of degenerative and inflammatory diseases.
PL2118074T3 (pl) Związki chemiczne do celów profilaktyki i leczenia chorób układu sercowo-naczyniowego
ZA201006868B (en) Aminodihydrothiazine derivatives as bace inhibitors for the treatment of alzheimer's disease
IL194076A0 (en) Imidazolothiazole compounds for the treatment of disease
IL204886B (en) A pharmaceutical preparation for the treatment of disorders of the stomach and intestines independent of food consumption
ZA201006752B (en) Spiro-indole derivatives for the treatment of parasitic disease
IL209816A0 (en) Combination of pilocarpin and methimazol for treating charcot-marietooth disease and related disorders
ZA201005116B (en) 6.7-dialkoxy ouinazoline derivatives useful for treatment of cancer related disorders
HK1141708A1 (en) Agent for treatment of pulmonary disease
EP2398789A4 (en) SPIROPYRROLIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
ZA201100165B (en) Use of hdac inhibitors for the treatment of hodgkin's disease
GB0816269D0 (en) Naphthoquinone derivatives useful for prevention of amyloid deposits and treatment of alzheimers disease
GB0604780D0 (en) Use of substituted piperazine compounds for the treatment of food related disorders
EP2370087A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF FLUID RETENTION DISORDERS
SI2278962T1 (sl) Postopki za zdravljenje dermatoloških motenj
GB0604782D0 (en) Use of substituted pyrimidinyl-2-piperazine compounds for the treatment of food related disorders
HK1185345A1 (zh) 用於預防和治療心血管疾病的化合物
IL208127A0 (en) Ptph1 inhibitors for the treatment of alzheimer's disease
AU2007907088A0 (en) Use of Naltrexone for Treating Alzheimers Disease
GB0618309D0 (en) Compositions and methods for the treatment of disease
GB0715257D0 (en) Phenylthiazolylpiperazine derivatives for the treatment of nuero degenerative diseases
GB0604775D0 (en) Use Of Substituted Benzimidazole Sulfonamide Compounds For The Treatment Of Food Related Disorders